Computed Tomography (CT) Devices Market

Computed Tomography (CT) Devices Market by Type (Stationary CT Scanners and Portable CT Scanners), Modality (O-Arm and C-Arm), Technology (Low End, Mid-End, and High End), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospitals, Diagnostic Imaging Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of chronic diseases, increase in technological advancement, and increase in product development activities by key market players across the globe.

The computed tomography devices market was valued at USD 8,400.69 million in 2024, growing at a CAGR of 6.15% during the forecast period from 2025 to 2032 to reach USD 13,460.21 million by 2032. The rising prevalence of chronic diseases, such as cancer, cardiovascular disorders, and respiratory illnesses, significantly increases the demand for diagnostic imaging, making computed tomography (CT) devices essential for early detection and monitoring. Additionally, technological advancements, including faster scanning speeds, enhanced image resolution, and lower radiation exposure, make CT devices more efficient and safer, encouraging wider adoption by healthcare providers. Furthermore, key market players are continuously developing innovative products, such as portable and AI-integrated CT systems, which improve diagnostic accuracy and expand the application of CT devices in various medical fields. Collectively, these factors are expected to boost the market for computed tomography devices during the forecast period from 2025 to 2032. 

Computed Tomography Devices Market Dynamics:

According to the latest data from the Australian Institute of Health and Welfare, approximately 8.5 million people (34% of the population) in Australia were estimated to have chronic respiratory conditions in 2022. Additionally, data from the Global Burden of Disease (2023) indicates that around 1 in 20 people worldwide suffer from chronic respiratory diseases. 

Respiratory conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, and lung cancer require precise imaging for accurate diagnosis, monitoring, and treatment planning. Computed tomography (CT) devices play a critical role in providing detailed cross-sectional images of the lungs, enabling early detection of abnormalities and assessment of disease progression. As the prevalence of respiratory diseases rises globally, the demand for CT devices continues to grow. 

Cancer is another major driver of CT device adoption. According to GLOBOCAN (2024), an estimated 20 million new cancer cases were reported worldwide in 2022, with projections expected to rise to 32.6 million by 2045. CT scans are essential for detecting tumors, determining their size and location, assessing blood supply, and evaluating cancer spread to organs such as the lungs or liver. Additionally, they play a vital role in CT-guided biopsies and treatments like radiofrequency ablation (RFA). The increasing global cancer burden underscores the need for advanced imaging technologies, thereby fueling the expansion of the CT device market. 

Similarly, cardiovascular diseases (CVDs) represent a significant health concern worldwide. According to the British Heart Foundation (2024), approximately 620 million people roughly 1 in 13 individuals are living with heart and circulatory diseases. In 2021 alone, the prevalence of CVDs reached 100 million in Europe and 340 million in Asia and Australia. Coronary (ischemic) heart disease, the most commonly diagnosed cardiovascular condition, affects an estimated 200 million people globally. CT angiography is crucial for non-invasive visualization of blood vessels, detection of blockages, and assessment of heart conditions. The rising incidence of cardiovascular diseases has led to an increased demand for CT imaging to prevent complications such as heart attacks and strokes, further driving market growth. 

In addition to increasing disease prevalence, strategic initiatives by key market players are also propelling the adoption of CT technology. For instance, in May 2021, Royal Philips introduced its spectral detector-based Spectral CT 7500, designed to deliver high-quality spectral images for every patient scan. This advanced system enhances disease characterization, minimizes the need for rescans and follow-ups, and maintains radiation dose levels comparable to conventional scans. 

Despite these growth drivers, challenges such as radiation exposure risks and stringent regulatory requirements for product approvals may hinder the expansion of the global CT device market. However, continued advancements in imaging technology and the increasing demand for early disease detection are expected to support sustained market growth during the forecast period.

Computed Tomography Devices Market Segment Analysis:

Computed Tomography (CT) Devices Market by Type (Stationary CT Scanners and Portable CT Scanners), Modality (O-Arm and C-Arm), Technology (Low End, Mid-End, and High End), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospitals, Diagnostic Imaging Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) 

In the type segment of the computed tomography (CT) devices market, the portable CT scanner category is expected to grow at the fastest CAGR during the forecast period from 2025 to 2032. The growing adoption of portable CT scanners is significantly driving market expansion by addressing key limitations of traditional, fixed CT systems. These mobile units provide enhanced flexibility and accessibility, particularly in emergency and critical care settings where rapid diagnostic imaging is crucial. 

Portable CT scanners are particularly beneficial in intensive care units (ICUs), operating rooms, and trauma centers, as they enable real-time imaging without requiring critically ill patients to be transported to a radiology department. This not only streamlines workflow efficiency but also improves patient outcomes by ensuring timely and accurate diagnoses. 

Furthermore, increasing strategic initiatives by key market players are propelling the adoption of portable CT technology. For example, in October 2022, NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced that its Elite Mobile Computed Tomography (CT) systems received CE marking under the European Union’s Medical Device Regulation (MDR 2017/745). The certification, granted by the EU’s Notified Body, approved the OmniTom Elite, BodyTom Elite, and CereTom Elite mobile CT systems, reinforcing their compliance with stringent regulatory standards and expanding their market presence. 

With the rising demand for point-of-care imaging solutions, the portable CT scanner segment is expected to grow, contributing significantly to the overall growth of the global computed tomography devices market during the forecast period. 

North America is expected to dominate the overall computed tomography devices market:

North America is expected to hold the largest share of the global computed tomography (CT) devices market in 2024, driven by the rising incidence of cancer, respiratory diseases, and cardiovascular disorders, as well as continuous technological advancements and an increase in product approvals and launches. 

According to GLOBOCAN (2024), North America recorded approximately 2.67 million new cancer cases in 2022, with projections expected to rise to 3.83 million by 2045. CT scans play a critical role in oncology by aiding in tumor detection, cancer progression assessment, and treatment planning, making the increasing cancer burden a key driver of CT device demand in the region. 

Additionally, cardiovascular diseases are a major health concern, further fueling the market. According to the Centers for Disease Control and Prevention (CDC, 2024), around 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022, and an estimated 12.1 million Americans were projected to have atrial fibrillation by 2023. Moreover, over 795,000 people in the U.S. experience a stroke annually, with approximately 610,000 being first-time strokes, while nearly 185,000 recurrent strokes occur each year. As cardiovascular diseases continue to rise, the demand for CT imaging in heart disease diagnosis and management is expected to grow significantly. 

Another major factor contributing to the expansion of the CT devices market in North America is the high utilization of medical imaging, particularly in the United States. Among Medicare beneficiaries, the use of medical imaging has consistently outpaced other physician-provided services, highlighting the increasing reliance on advanced imaging technologies for accurate diagnosis and treatment planning. This growing adoption of CT scans is expected to create a favorable market environment. 

Additionally, extensive product development activities and regulatory approvals in the region further support market growth. In October 2021, Siemens Healthineers received FDA 510(k) clearance for the Naeotom Alpha, the world’s first photon-counting CT scanner, which offers enhanced imaging precision while reducing radiation exposure. 

These technological advancements, combined with rising disease prevalence and increased CT scan utilization, are expected to drive the North American CT devices market forward during the forecast period.

Computed Tomography Devices Market Key Players:

Some of the key market players operating in the computed tomography devices market include General Electric Company, FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, NeuroLogica Corp. (Samsung Electronics), Shimadzu Corp., Thermo Fisher Scientific, Xoran Technologies LLC, Trivitron Healthcare, Neusoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech Co. Ltd., Shenzhen Basda Medical Apparatus Co. Ltd., PerkinElmer Inc., ICRco, Inc., MARS Bioimaging Ltd., United Imaging Healthcare Co., Ltd., SternMed GmbH, MinFound Medical Systems Co., Ltd., MR Solutions, and others.

Recent Developmental Activities in the Computed Tomography Devices Market:

• In Sept 2025, 4DMedical received FDA 510(k) clearance for CT:VQ™, the first non-contrast ventilation–perfusion (VQ) imaging solution. CMS confirmed reimbursement under Category III CPT codes, supplementing chest CT payments. CT:VQ software converts standard chest CTs into detailed lung ventilation and perfusion maps, integrating seamlessly into radiology workflows and expanding functional lung imaging access without nuclear medicine.
• In August 2025, DeepHealth, Inc., a RadNet subsidiary, received FDA 510(k) clearance for TechLive™ — a remote scanning solution for centralized control of MR, CT, PET/CT, and Ultrasound procedures. TechLive™ helps address tech labor shortages by allowing technologists to operate scans across multiple locations, improving efficiency, extending hours, and boosting patient access. Over 300 RadNet imaging systems now use TechLive™, increasing patient throughput and enhancing quality with real-time expert support.
• In May 2025, GE HealthCare (Nasdaq: GEHC) launched CleaRecon DL, an AI-powered deep-learning technology that enhances cone-beam CT (CBCT) image quality. Designed for use in liver, prostate, neuro, and endovascular aortic repair procedures, it reduces streak artifacts from blood flow and contrast changes. CleaRecon DL has received U.S. FDA 510(k) clearance and CE mark, and will be available on the Allia™ platform.
• In May 2025, GE HealthCare announced that the FDA granted 510(k) clearance for its Aurora nuclear medicine system and Clarify DL. This advanced dual-head SPECT/CT system is designed to enhance diagnostic capabilities and improve workflow efficiency, providing clinicians with superior image quality and streamlined operations.
• In April 2025, Brainomix announced FDA clearance of a novel feature in its Brainomix 360 Stroke solution that allows physicians to assess ischemic core volume using standard non-contrast CT (NCCT) images. This feature, validated by leading US stroke centers, shows accuracy comparable to CT Perfusion and MRI assessments.
• In March 2025, the FDA granted 510(k) clearance for Johnson & Johnson (J&J) MedTech’s Monarch Quest for robotic-assisted bronchoscopy procedures. This solution features AI-powered algorithms and a verified OEC Open interface with GE HealthCare’s OEC 3D mobile cone-beam CT imaging system, marking a new advancement in Monarch navigation technology.
• In March 2025, Fovia Ai, Inc., a leader in AI analysis and workflow software, received FDA 510(k) clearance for F.A.S.T.® aiCockpit® CT Lung Nodule through its parent company, Fovia, Inc. This application helps radiologists efficiently visualize, navigate, edit, and accept or reject lung nodule detection algorithm results.
• In July 2024, Trivitron Healthcare announced the launch of its advanced CT scanner, ""Terrene,"" which became the first in India to receive approvals from the Bureau of Indian Standards (BIS), the Atomic Energy Regulatory Board (AERB), and the Central Drugs Standard Control Organization (CDSCO), marking a significant milestone in the country's healthcare industry.
• In April 2022, Wipro GE Healthcare announced the launch of its next-generation Revolution Aspire CT scanner, designed and manufactured entirely in India at the Wipro GE Medical Devices Manufacturing plant. This advanced imaging solution, aligned with the ‘Atmanirbhar Bharat’ initiative, features enhanced imaging intelligence to improve clinical confidence in diagnosing diseases and anomalies.

Key Takeaways From the Computed Tomography Devices Market Report Study:

• Market size analysis for current computed tomography devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the computed tomography devices market.
• Various opportunities available for the other competitors in the computed tomography devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current computed tomography devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for computed tomography devices market growth in the coming future?

Target Audience Who Can be Benefited From This Computed Tomography Devices Market Report Study:

• Computed tomography device product providers
• Research organizations and consulting companies 
• Computed tomography devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in computed tomography devices 
• Various end-users who want to know more about the computed tomography devices market and the latest technological developments in the computed tomography devices market. 

Frequently Asked Questions for the Computed Tomography Devices Market:

1. What are computed tomography devices?

• Computed Tomography (CT) devices, also known as CT scanners, are advanced medical imaging systems that use X-rays and computer processing to create detailed cross-sectional images of the body. These images provide a three-dimensional view of the internal structures, allowing for accurate diagnosis and treatment planning.

2. What is the market for computed tomography devices?

• The computed tomography devices market was valued at USD 8,400.69 million in 2024, growing at a CAGR of 6.15% during the forecast period from 2025 to 2032 to reach USD 13,460.21 million by 2032. 

3. What are the drivers for the computed tomography devices market?

• The rising prevalence of chronic diseases, such as cancer, cardiovascular disorders, and respiratory illnesses, significantly increases the demand for diagnostic imaging, making computed tomography (CT) devices essential for early detection and monitoring. Additionally, technological advancements, including faster scanning speeds, enhanced image resolution, and lower radiation exposure, make CT devices more efficient and safer, encouraging wider adoption by healthcare providers. Furthermore, continuous innovation in products, such as portable and AI-integrated CT systems, improves diagnostic accuracy and expands the application of CT devices in various medical fields. Collectively, these factors are expected to boost the market for computed tomography devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the computed tomography devices market?

• Some of the key market players operating in the Computed Tomography Devices market include General Electric Company, FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, NeuroLogica Corp. (Samsung Electronics), Shimadzu Corp., Thermo Fisher Scientific, Xoran Technologies LLC, Trivitron Healthcare, Neusoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech Co. Ltd., Shenzhen Basda Medical Apparatus Co. Ltd., PerkinElmer Inc., ICRco, Inc., MARS Bioimaging Ltd., United Imaging Healthcare Co., Ltd., SternMed GmbH, MinFound Medical Systems Co., Ltd., MR Solutions, and others.

5. Which region has the highest share in the computed tomography devices market?

• Among all the regions, North America is expected to hold the largest share of the global computed tomography devices market in 2024. The key driving factors of the computed tomography devices market are the rising incidence of cancer cases, respiratory diseases, and cardiovascular disorders, technological advancements in CT devices, and increased product approval and launches in the region are expected to aid in the growth of the North America computed tomography devices market.